ARTICLE | Emerging Company Profile
Vaxxinity: supplanting mAbs with vaccines for chronic disease
Emerging Company Profile: after its COVID-19 vaccine, Vaxxinity plans to take on mAbs for chronic diseases with vaccines against the same targets
November 7, 2020 3:40 AM UTC
Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But first, it intends to deliver 100 million doses of a COVID-19 vaccine by 1Q21.
Just seven months old, Vaxxinity is still in the process of being formed through the merger of its two predecessor entities, United Neuroscience Inc. and the Covaxx unit of United Biomedical Inc. The two already share a management team and have been using the same vaccine platform for different purposes. ...